Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.
Good afternoon, everyone, and welcome to IDACORP's Second Quarter 2026 Earnings Call. Today's call is being recorded, and our webcast is live. A replay will be available later today and for the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results